Gilead Sciences, Inc. (GILD) Stake Boosted by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,275 shares of the biopharmaceutical company’s stock after purchasing an additional 1,038 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Gilead Sciences were worth $1,831,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Advisors Preferred LLC bought a new position in Gilead Sciences during the fourth quarter valued at about $31,000. Legacy Financial Advisors Inc. increased its stake in Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 383 shares during the period. We Are One Seven LLC bought a new position in Gilead Sciences during the fourth quarter valued at about $37,000. Jackson Grant Investment Advisers Inc. increased its stake in Gilead Sciences by 56.9% during the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 717 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 260 shares during the period. Finally, CKW Financial Group bought a new position in Gilead Sciences during the fourth quarter valued at about $56,000. Institutional investors and hedge funds own 80.03% of the company’s stock.

Several equities analysts recently issued reports on GILD shares. Raymond James restated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, November 1st. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 24th. Piper Jaffray Companies lowered Gilead Sciences from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $85.00 to $75.00 in a research note on Friday, October 26th. Morgan Stanley boosted their price target on Gilead Sciences from $85.00 to $86.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 19th. Finally, Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, October 31st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $86.85.



Shares of GILD opened at $67.62 on Tuesday. The company has a market capitalization of $87.28 billion, a PE ratio of 11.00, a price-to-earnings-growth ratio of 66.65 and a beta of 1.19. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.29 and a current ratio of 3.36. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $82.71.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm’s revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.78 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 6.23 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be issued a $0.63 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a dividend yield of 3.73%. The ex-dividend date of this dividend is Thursday, March 14th. Gilead Sciences’s payout ratio is presently 37.07%.

In other news, Director John C. Martin sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $71.20, for a total value of $3,560,000.00. Following the transaction, the director now directly owns 2,877,762 shares of the company’s stock, valued at approximately $204,896,654.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.16% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Stake Boosted by Benjamin F. Edwards & Company Inc.” was originally reported by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://dakotafinancialnews.com/2019/02/12/gilead-sciences-inc-gild-stake-boosted-by-benjamin-f-edwards-company-inc.html.

Gilead Sciences Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: How to Track your Portfolio in Google Finance

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply